Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D. Wiviott, Marc S. Sabatine, Eri Kato et al.|New England Journal of Medicine|2018Cited by 6.3k
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trialOfri Mosenzon, Itamar Raz, Stephen D. Wiviott et al.|The Lancet Diabetes & Endocrinology|2019Cited by 673